Enhancing Capital LLC Invests $6.41 Million in Eli Lilly and Company (NYSE:LLY)

Enhancing Capital LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 8,300 shares of the company’s stock, valued at approximately $6,408,000. Eli Lilly and Company accounts for about 5.1% of Enhancing Capital LLC’s investment portfolio, making the stock its 2nd biggest holding.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Halter Ferguson Financial Inc. increased its position in shares of Eli Lilly and Company by 16.6% during the fourth quarter. Halter Ferguson Financial Inc. now owns 6,801 shares of the company’s stock worth $5,250,000 after acquiring an additional 968 shares in the last quarter. Generali Asset Management SPA SGR bought a new stake in Eli Lilly and Company in the 4th quarter worth about $54,907,000. Evoke Wealth LLC increased its stake in Eli Lilly and Company by 2.9% in the 4th quarter. Evoke Wealth LLC now owns 7,466 shares of the company’s stock valued at $5,764,000 after buying an additional 211 shares during the last quarter. Horizon Investments LLC lifted its position in shares of Eli Lilly and Company by 64.3% during the 4th quarter. Horizon Investments LLC now owns 8,932 shares of the company’s stock worth $6,896,000 after buying an additional 3,497 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Eli Lilly and Company by 9.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 468,736 shares of the company’s stock valued at $362,875,000 after acquiring an additional 40,776 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 1.5 %

LLY opened at $825.48 on Tuesday. The firm has a market capitalization of $782.70 billion, a P/E ratio of 70.49, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company has a fifty day moving average price of $832.05 and a 200-day moving average price of $841.68. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has approved a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LLY shares. Bank of America restated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Friday, January 17th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Finally, StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.